BI-3812 is primarily used in cancer research due to its ability to inhibit the BET (Bromodomain and Extra-Terminal) family of proteins. These proteins play a crucial role in regulating gene expression, particularly in cancer cells. By targeting BET proteins, BI-3812 helps suppress the growth and proliferation of cancer cells, making it a promising candidate for the development of novel anticancer therapies. Its application is particularly significant in studying hematologic malignancies and solid tumors, where BET inhibition has shown potential in disrupting oncogenic pathways. Researchers also explore its use in combination with other therapeutic agents to enhance treatment efficacy and overcome drug resistance.